Summary

Generics in Europe

Summary

Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The European generics market recorded revenues of $102.7 billion in 2024, representing a compound annual growth rate (CAGR) of 5.8% between 2019 and 2024.
- Market consumption volume increased with a CAGR of 1.5% between 2019 and 2024, reaching a total of 55.6 % of total pharma volume in 2024.
- In 2024, the revenue of the European generics market experienced an annual growth of 5.9%. The market’s growth is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions, increasing the demand for affordable, long-term medications.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the Europe generics market by value in 2024?
- What will be the size of the Europe generics market in 2029?
- What factors are affecting the strength of competition in the Europe generics market?
- How has the market performed over the last five years?
- What are the main segments that make up Europe's generics market?

ページTOPに戻る

Table of Contents

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strategies of the leading players?
7.3. Have there been any recent developments in the market?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Ltd
8.2. Novartis AG
8.3. Sandoz Group AG
8.4. Hikma Pharmaceuticals Plc
8.5. Sanofi
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1: Europe generics market value: $ million, 2019-24
Table 2: Europe generics market volume: % of total pharma volume, 2019-24
Table 3: Europe generics market geography segmentation: $ million, 2024
Table 4: Europe generics market value forecast: $ million, 2024-29
Table 5: Europe generics market volume forecast: % of total pharma volume, 2024-29
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Novartis AG: Key Facts
Table 10: Novartis AG: Annual Financial Ratios
Table 11: Novartis AG: Key Employees
Table 12: Sandoz Group AG: Key Facts
Table 13: Sandoz Group AG: Annual Financial Ratios
Table 14: Sandoz Group AG: Key Employees
Table 15: Hikma Pharmaceuticals Plc: Key Facts
Table 16: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 17: Hikma Pharmaceuticals Plc: Key Employees
Table 18: Sanofi: Key Facts
Table 19: Sanofi: Annual Financial Ratios
Table 20: Sanofi: Key Employees
Table 21: Sanofi: Key Employees Continued
Table 22: Europe Size of Population (Million), 2020-24
Table 23: Europe Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 24: Europe GDP (Current Prices, $ Billion), 2020-24
Table 25: Europe Inflation, 2020-24
Table 26: Europe Consumer Price Index (Absolute), 2020-24
Table 27: Europe Exchange Rate, 2019-24